Scientists at Oregon State University have engineered a powerful new nanomaterial that zeroes in on cancer cells and destroys them from the inside out. Designed to exploit cancer’s unique ...

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

Cancer remains one of the leading causes of morbidity and mortality worldwide, despite significant advances in molecular biology, targeted therapy, and ...

Cancer research continues to evolve as scientists strive to unravel the complexities of tumor biology, molecular signaling, and metabolic adaptations.